Therachon hires Catalent to make protein dwarfism drug for Ph I trial

By Gareth Macdonald contact

- Last updated on GMT

Therachon hires Catalent to make protein dwarfism drug for Ph I trial

Related tags: Pharmacology

Therachon AG has contracted Catalent Biologics to manufacture a candidate protein therapeutic for a rare form of dwarfism.

Catalent will produce TA-46, a soluble version of a protein called fibroblast growth factor receptor 3 (FGFR3) that is mutated in the disease achondroplasia, also known as short-limbed dwarfism.

The idea is that TA-46 acts as a decoy and prevents fibroblast growth factor (FGF) from binding the mutated receptor, thereby allowing normal growth to resume. Catalent will produce the drug for a Phase I trial due to start next year.

The US CMO has been involved in the project for more than a year, using its GPex expression technology to produce a range of TA-46 variants from which Therachon selected the most promising preclinical candidate.

Manufacture of TA-46 for trials will take place at Catalent’s biomanufacturing facility in Madison, Wisconsin. The CMO is currently increasing production capacity at the site, adding two 2,000 liter single use bioreactors in an expansion due to be completed in October.

Achondroplasia market

At present there are no treatments for achondroplasia, however, Therchon is not the only firm with a candidate in the pipeline.

BioMarin Pharmaceuticals has vosoritide (BMN-111), an analog of C-type natriuretic eptide (CNP), in a Phase III​ trial. Denmark based Ascendis Pharma A/S has TransCon CNP, which is a sustained-release prodrug of CNP.

US-based BioClin Therapeutics Inc is also developing an achondroplasia candidate. Like Therachon, the Californian biotech is targeting FGFR3.

Related news

Show more

Related products

show more

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars